Physician profile
Stephen A Mcclave
NPI 1619960648
$123,833.27
in general payments reported to CMS, 2019-2025
13 companies · $161 in 2025
The $161 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $9,021 · 2021: $8,798 · 2022: $50K · 2023: $28K · 2024: $201 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $19K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,000 · Food and Beverage: $2,229 · Travel and Lodging: $1,787.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $19,304.84 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,000.00 |
| Food and Beverage | $2,228.52 |
| Travel and Lodging | $1,787.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $73,818.87 | 2021-2023 | |
| Avanos Medical | $33,343.24 | 2019-2024 | Peg |
| Fresenius Kabi USA, LLC | $10,926.26 | 2022 | |
| Baxter Healthcare | $4,403.24 | 2019 | |
| Abbvie INC. | $747.27 | 2019-2025 | |
| Madrigal Pharmaceuticals | $143.36 | 2025 | Rezdiffra |
| Janssen Scientific Affairs, LLC | $131.81 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $101.35 | 2021 | |
| Alcresta Therapeutics, INC. | $95.08 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $62.75 | 2020-2021 | |
| Medtronic, INC. | $26.89 | 2021-2023 | Endoflip |
| Conmed Corporation | $18.13 | 2021 | |
| Evoke Pharma, INC. | $15.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Mcclave listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.